Soaring by 230%: Chinese Biotech Is No Longer a Bargain

Image source | Internet

As the echoes of the Spring Festival drums and gongs still linger, China's innovative drug BD has already galloped ahead — securing three major overseas deals within just two days.

Yesterday, Pfizer secured the commercial rights for Sinovant's enobrelglutide in mainland China for up to $495 million; On February 23, GSK acquired the global rights to two small nucleic acid assets from Frontier Biotech for over $1 billion; On the same day, Harbour BioMed's next-generation CTLA-4 inhibitor went global through NewCo, with an upfront payment exceeding $105 million and a cumulative total surpassing $1.2 billion. This highly "valuable" deal set a new record for China's CTLA-4 category outbound BD.

These three dense and high-priced deals are by no means a coincidental buzz, but an epitome of a fundamental reversal in the pricing logic of China's Biotech going global.

Data-Driven Proof: "Price Lowlands" Have Become History

If individual cases may still be accidental, then the data reveals an irreversible trend.

Evaluate's latest data shows that the average upfront payment for licensing collaborations between overseas pharmaceutical companies and Chinese Biotechs has surged from US$52 million in 2022 to US$172 million so far this year. In just two years, it skyrocketed by 230%!

As of now, the average upfront for the first two months of 2026 alone is higher than the annual average for 2025.22%If the current trend continues, the upfront payment amount in licensing agreements participated in by Chinese innovative pharmaceutical companies will continue to grow by 2026.

As Mark Lansdell, Chief Strategist of Evaluate, said:"This is no longer a market for bargain hunting."

Looking Back from 2022 to 2025: The Growth in the Number of Overseas Licensing Deals for China's Innovative Drugs120%(From 42 to 93), the total scale of down payments during the same period has soared.400%(From USD 1.1 billion to USD 5.6 billion).

From the end of 2025 to early 2026, multinational pharmaceutical companies such as AstraZeneca, AbbVie, and Sanofi took turns to act, making intensive moves. For instance, after AstraZeneca introduced the core KRAS pipeline from JAB Biotherapeutics, it spent a whopping $18.5 billion just over a month later to acquire multiple next-generation weight-loss and metabolic drug assets from CSPC Pharmaceutical Group in one package deal. This move directly pushed the price benchmark of the entire innovative drug BD track up significantly. $18.5 Billion! AstraZeneca and CSPC Reach Major Collaboration

Driven by the continuous global demand, Chinese pharmaceutical companies have begun to price their own innovative assets.Raised to a level comparable to that of their European and American counterparts——China's Biotech is bidding farewell to the era of being a "price lowland" in global BD.

Role Remodeling: From "Scavenger Market" to "Must-Have Asset"

If we turn back the clock three years, the label of being "cheap" was once a persistent stereotype hanging over China's innovative drug industry.

The "low cost" at that time was not due to quality, but rather because China's innovative drug industry had just established technical barriers, with limited global recognition and overseas experience, allowing multinational pharmaceutical companies to hold an absolute advantage at the negotiating table.

However, this label is fading rapidly.

Twenty Years to Sharpen a Sword, ChinaBiopharmaceuticalsAchieved a "triple jump": from initially doing outsourcing and conducting experiments, to starting to output its own R&D pipeline, and then to being able to sell off core assets in the clinical stage as a whole – the role in the industry has undergone a dramatic change.

Today, China has become a "main force" in several major global hot fields. According to Evaluate, in the bispecific antibody field, Chinese assets account for 48% of all clinical stage projects. In the ADC track, 51% of ADC clinical trials include products from Chinese pharmaceutical companies. Even in the CAR-T field, which has extremely high technical barriers, 48% of drug candidate trials involve assets originating from China.

This widespread presence means that multinational pharmaceutical companies, if they want to fill their pipeline, can hardly bypass China. Even with price increases, buyers will struggle to find many alternative options.

Script Rewriting, Value Return

As China's asset quality becomes more robust, global demand strengthens, and the upper hand at the negotiating table gradually returns to China.BiotechIn hand.

As the three major heavyweight licenses at the beginning of 2026 are all finalized, the chapter of China's innovative drug exports has been rewritten:Chinese innovation is no longer cheap, pipeline assets are no longer undervalued, and Chinese Biotech is no longer the discount zone for global BD.

The moment the industry has been waiting for has indeed arrived. This time, the pricing power firmly rests in the hands of China's Biotech companies.

       Title: Surge of 230%! Chinese Biotech Finally Isn't Cheap Anymore